The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells

[1]  B. Leber,et al.  The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. , 2010, Blood.

[2]  J. Tamburini,et al.  Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies , 2010, Leukemia.

[3]  T. Naoe,et al.  Irrespective of CD34 expression, lineage‐committed cell fraction reconstitutes and re‐establishes transformed Philadelphia chromosome‐positive leukemia in NOD / SCID / IL‐2Rγc−/− mice , 2010, Cancer science.

[4]  Jing Chen,et al.  Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor , 2010, Nature Medicine.

[5]  T. Clackson,et al.  AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.

[6]  H. Kantarjian,et al.  Imatinib and beyond—exploring the full potential of targeted therapy for CML , 2009, Nature Reviews Clinical Oncology.

[7]  P. Majumder,et al.  Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. , 2009, Blood.

[8]  Funda Meric-Bernstam,et al.  Targeting the mTOR signaling network for cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Dyer,et al.  Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. , 2009, The Journal of clinical investigation.

[10]  P. Kearns,et al.  Expression of CD133 on leukemia-initiating cells in childhood ALL. , 2009, Blood.

[11]  R. Crazzolara,et al.  Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. , 2009, Blood.

[12]  T. Naoe,et al.  BCR-ABL-transformed GMP as myeloid leukemic stem cells , 2008, Proceedings of the National Academy of Sciences.

[13]  David E. Housman,et al.  mTORC1 promotes survival through translational control of Mcl-1 , 2008, Proceedings of the National Academy of Sciences.

[14]  J. Okamura,et al.  CD34+CD38+CD19+ as well as CD34+CD38−CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL , 2008, Leukemia.

[15]  T. Enver,et al.  Initiating and Cancer-Propagating Cells in TEL-AML1-Associated Childhood Leukemia , 2008, Science.

[16]  R. V. van Etten,et al.  Right on target: eradicating leukemic stem cells. , 2007, Trends in molecular medicine.

[17]  Satoshi Tanaka,et al.  Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region , 2007, Nature Biotechnology.

[18]  Y. Pan,et al.  Increased phosphorylation of p70 S6 kinase is associated with HPV16 infection in cervical cancer and esophageal cancer , 2007, British Journal of Cancer.

[19]  C. Jordan.  The leukemic stem cell. , 2007, Best practice & research. Clinical haematology.

[20]  T. Naoe,et al.  Establishment of a Stroma-Dependent Human Acute Myelomonocytic Leukemia Cell Line, NAMO-2, with FLT3 Tandem Duplication , 2006, International journal of hematology.

[21]  Ingo Roeder,et al.  Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications , 2006, Nature Medicine.

[22]  M. Konopleva,et al.  Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies , 2006, Clinical Cancer Research.

[23]  G. Lenz,et al.  Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph^+ALL) , 2006 .

[24]  S. Morrison,et al.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.

[25]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[26]  B. Druker,et al.  Targeted CML therapy: controlling drug resistance, seeking cure. , 2006, Current opinion in genetics & development.

[27]  M. Carroll,et al.  mTOR regulates cell survival after etoposide treatment in primary AML cells. , 2005, Blood.

[28]  P. Codogno,et al.  Autophagy and signaling: their role in cell survival and cell death , 2005, Cell Death and Differentiation.

[29]  Martin A. Nowak,et al.  Dynamics of chronic myeloid leukaemia , 2005, Nature.

[30]  S. Forman,et al.  Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli , 2005, Leukemia.

[31]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[32]  D. Neuberg,et al.  Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Naoe,et al.  Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. , 2003, Blood.

[34]  H. Saito,et al.  Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors , 2002, Leukemia.

[35]  C. Eaves,et al.  Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. , 1999, Blood.

[36]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[37]  F. E. Bertrand,et al.  Targeting the leukemic stem cell: the Holy Grail of leukemia therapy , 2009, Leukemia.

[38]  T. Naoe,et al.  Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice , 2007, Leukemia.